Explained: Testosterone deficiency and the safety of replacement therapy | Explained News,The Indian Express
Testosterone replacement therapy is the standard treatment for hypogonadism, which can cause sexual dysfunction, weakening of bones and muscles, and reduced quality of life.
Hypogonadism is a condition caused by the deficiency of the male sex hormone, testosterone, and a new study in Lancet Health Longevity looks at the short- to medium-term safety of testosterone treatment. Analysis of data from more than 3,400 patients with hypogonadism from 17 clinical trials found little evidence that testosterone treatment increases the risk of cardiovascular events such as arrhythmia, heart attack, and stroke, in the short to medium terms.
Testosterone replacement therapy is the standard treatment for hypogonadism, which can cause sexual dysfunction, weakening of bones and muscles, and reduced quality of life. Risk factors include ageing (as testosterone levels decline with age), obesity and diabetes. Contacted via email, Dr Channa Jayasena, Reader in Reproductive Endocrinology, Imperial College London and study author, said that worldwide, 2% of men aged over 40 are affected, and this is growing as the population gets older.
Despite being widely used, the cardiovascular safety of testosterone treatment had so far remained unclear due to inconsistent findings. Most previous clinical studies relied on aggregate data, rather than individual participant data and have not published details of individual adverse events.
“Prescribing of testosterone for hypogonadism is increasing globally, but conflicting messages about its safety may have led to many patients not receiving the treatment. Ongoing studies should help to determine the longer-term safety of testosterone but, in the meantime, our results provide much-needed reassurance about its short-to-medium term safety. Our findings could have important implications for the treatment of men with hypogonadism worldwide,” lead author Jemma Hudson from the University of Aberdeen said in the report.
Funded by the UK National Institute for Health Research Health Technology Assessment Programme, the study identified 35 eligible clinical trials published since 1992, of which 17 provided individual participant data. None of the studies were from India, Dr Jayasena said.
Rating: 5